23andMe Announces Three Presentations from Clinical-Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024
March 05 2024 - 4:30PM
23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human
genetics and biopharmaceutical company, today announced an oral
presentation and two poster presentations on two of the Company’s
immuno-oncology programs that will be presented at the American
Association for Cancer Research (AACR) Annual Meeting 2024, taking
place in San Diego, CA, April 5-10, 2024.
The oral presentation will detail the use of the 23andMe genetic
and health survey database to discover ULBP6, the highest affinity
ligand of the NK and T-cell activation receptor, NKG2D. ULBP6 is
the primary target for 23ME-01473 (‘1473), a dual mechanism
monoclonal antibody. The Company will also present a poster on the
biology of ULBP6, and how ‘1473 reinvigorates anti-tumor NK cell
function through NKG2D and FcγRIIIa activation.
These presentations will be the first scientific communications
the Company has prepared on ‘1473 since announcing its pursuit of
this novel, genetically-validated target. The FDA recently cleared
the IND application for ‘1473, which targets ULBP6. Cancers escape
immune cell recognition by shedding ULBP ligands from their cell
surface, which act as immunosuppressive molecular decoys. Blocking
the binding of soluble ULBP6 to NKG2D with ‘1473 may restore immune
cell recognition and killing of cancers. Further, ‘1473 is
Fc-effector enhanced, which provides an additional mechanism for NK
cells to induce cell death of ULBP6-expressing cancer cells.
23andMe will also present a non-clinical poster on 23ME-00610,
an inhibitor of the CD200R1 receptor, which will include new
insights into targeting the CD200R1 pathway in T and NK cells using
23ME-00610 as a single agent or in combination with other
anti-tumor therapies. 23ME-00610 is currently in Phase 2a of a
Phase 1/2a clinical study.
The presentations will be available on the 23andMe Investor
Relations and Therapeutics websites on April 5, 2024.
Presentation details - 23ME-01473:
Oral presentation
- Title: Discovery of ULBP6 as a novel
immuno-oncology target using pleiotropic signals from 23andMeʼs
genetic and health survey database
- Session Type: Minisymposium
- Session Category: Experimental and Molecular
Therapeutics
- Session Title: Drug Discovery 1: New Targets
and Approaches
- Session Date and Time: Monday, April 8, 2024,
2:30 - 4:30 PM PT
- Published Abstract Number: 3903
Poster presentation
- Title: 23ME-01473, a novel anti-ULBP6/2/5
monoclonal antibody, reinvigorates anti-tumor NK cell function
through NKG2D and FcγRIIIa activation
- Session Category: Clinical Research
- Session Title: Antibodies 1
- Session Date and Time: Monday, April 8, 2024,
9:00 AM - 12:30 PM PT
- Location: Poster Section 38
- Poster Board Number: 21
- Published Abstract Number: 2375
Presentation Details: 23ME-00610:
Poster presentation
- Title: New insights into targeting the CD200R1
pathway in T and NK cells using 23ME-00610 as a single agent or in
combination
- Session Category: Clinical Research
- Session Title: Antibodies 1
- Session Date and Time: Monday, April 8, 2024,
9:00 AM - 12:30 PM PT
- Location: Poster Section 38
- Poster Board Number: 5
- Published Abstract Number: 2359
About 23ME-01473 (‘1473)‘1473 targets ULBP6 to
restore anti-tumor immunity through NK and T cells. ULBPs are
stress-induced ligands found on the surface of cancer cells that
bind to their receptor, NKG2D, on NK and T cells. Cancers escape
immune cell recognition by shedding ULBP ligands from their cell
surface, which act as immunosuppressive molecular decoys. Blocking
the binding of soluble ULBP6 to NKG2D may restore immune cell
recognition and killing of cancers. Further, ‘1473 is Fc-effector
enhanced, which provides an additional mechanism for NK cells to
induce cell death of ULBP6-expressing cancer cells. 23andMe plans
to evaluate ‘1473 in participants with advanced solid tumors in a
Phase 1 clinical study beginning in the first half of 2024.
Clinical trials registry (clinicaltrials.gov): NCT06290388.
About 23ME-0061023ME-00610 is a high-affinity,
fully humanized monoclonal antibody that is designed to bind to
CD200R1 and prevent the interaction of CD200R1 with CD200. The
CD200–CD200R1 axis is an immunological checkpoint that plays a
pivotal role in maintenance of immune tolerance. CD200R1 is an
inhibitory receptor expressed on T cells and myeloid cells while
CD200, the ligand for CD200R1, is highly expressed on certain
tumors. In preclinical studies, binding of tumor-associated CD200
to CD200R1 leads to immune suppression and decreased immune cell
killing of cancer cells. Preclinical data indicate that this
mechanism has the potential to restore the ability for both T-cells
and myeloid cells to kill cancer cells. Clinical trials registry
(clinicaltrials.gov): NCT05199272.
About 23andMe23andMe is a genetics-led consumer
healthcare and biopharmaceutical company empowering a healthier
future. For more information, please visit
www.23andMe.com.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended, including, without
limitation, statements regarding the future plans of 23andMe’s
therapeutics business. All statements, other than statements of
historical fact, included or incorporated in this press release,
including statements regarding 23andMe’s strategy, the plans for
and results of its clinical trials and objectives of management,
are forward-looking statements. The words "believes,"
"anticipates," "estimates," "plans," "expects," "intends," "may,"
"could," "should," "potential," "likely," "projects," “predicts,”
"continue," "will," “schedule,” and "would" or, in each case, their
negative or other variations or comparable terminology, are
intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words. These
forward-looking statements are predictions based on 23andMe’s
current expectations and projections about future events and
various assumptions. 23andMe cannot guarantee that it will actually
achieve the plans, intentions, or expectations disclosed in its
forward-looking statements and you should not place undue reliance
on 23andMe’s forward-looking statements. These forward-looking
statements involve a number of risks, uncertainties (many of which
are beyond the control of 23andMe), or other assumptions that may
cause actual results or performance to differ materially from those
expressed or implied by these forward-looking statements. The
forward-looking statements contained herein are also subject
generally to other risks and uncertainties that are described from
time to time in the Company’s filings with the Securities and
Exchange Commission, including under Item 1A, “Risk Factors” in the
Company’s most recent Annual Report on Form 10-K, as filed with the
Securities and Exchange Commission, and as revised and updated by
our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.
The statements made herein are made as of the date of this press
release and, except as may be required by law, 23andMe undertakes
no obligation to update them, whether as a result of new
information, developments, or otherwise.
Contacts: Investor Relations Contact:
investors@23andMe.comMedia Contact: press@23andMe.com
23andMe (NASDAQ:ME)
Historical Stock Chart
From Sep 2024 to Oct 2024
23andMe (NASDAQ:ME)
Historical Stock Chart
From Oct 2023 to Oct 2024